Avalon Globocare Corp. · NASDAQ:ALBT
Avalon Globocare — Merger or Acquisition (September 2025)
16 slides from Avalon Globocare's merger presentation, Sep 8, 2025
Slide 1: September 2025 Corporate Presentation
www.avalon - globocare.com Nasdaq: ALBT September 202 5 Corporate Presentation
Slide 2: Forward-Looking Statements
Forward - Looking Statements 2 2 Certain statements contained in this presentation may constitute “forward - looking statements”, which provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact
Slide 3: Forward-Looking Statements: No Offer or Solicitation
Forward - Looking Statements 2 2 No Offer or Solicitation This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any proxy, consent, authorization, vote or approval, nor shall there be any sale of securities in any jurisdi
Slide 4: Forward-Looking Statements: YOOV Preliminary Financial Data
Forward - Looking Statements 2 2 This investor presentation contains additional information regarding YOOV , including certain preliminary financial data with respect to YOOV . The actual amounts that YOOV will report will be subject to its financial closing procedures and any final adjustments that
Slide 5: Corporate Overview and Highlights
Mission: Avalon GloboCare Corp. (Nasdaq: ALBT) is a developer of precision diagnostic consumer products and the advancement of intellectual property in cellular therapy. History: Founded in 2016; successfully uplisted to Nasdaq in December 2018; Headquarters in Freehold, New Jersey . Core Technology
Slide 6: Volatile Organic Compound (VOC) based Nanosensors Technology
Volatile Organic Compound (VOC) based Nanosensors Technology Multiple VOCs “Breathprint” POCT • AI - based computational algorithm • “Breathprint” VOC bomarkers and database • Single - use sensor cartridge for different disease detection • Point - of - care portable device Prototype for early detect
Slide 7: Intellectual Property
Summary Nanosensor Technology Nasdaq: ALBT 7 Jointly Filed Patents (including USPTO, PCT) • Detect and quantify acetone level in breath (home - use breathalyzer) • Monitor ketosis state • For optimization of ketogenic diet • Bundled with “AI Nutritionist” App Exclusive Distributor in N. America, Sou
Slide 8: Definitive Merger Agreement with YOOV
• Entered into definitive merger agreement on March 7, 2025 with YOOV Group Holding Limited (“YOOV”), an AI - as - a - Service ( AIaaS ) platform specializing in intelligent business automation through advanced AI and robotic process automation (RPA). Over 50 employees across Hong Kong, Malaysia, Au
Slide 9: YOOV Product
YOOV Product Nasdaq: ALBT 9 YOOV unlike many solutions that offer numerous models but lack practical applications, YOOV provides an AI - as - a - Service ( AIaaS ) framework for tailored AI implementation. With YOOV, Users can interact directly with their data and delegate tasks, streamlining proces
Slide 10: Competitive Landscape – Business AI Automation
Competitive Landscape – Business AI Automation Nasdaq: ALBT 10 Highly competitive market as enterprises and SMEs adopt automation for efficiency & advantage. • Large Enterprise Software Companies – Strong brands, advanced AI, but complex and enterprise - focused. • AI Model / Solution Providers – Of
Slide 11: YOOV Differentiation
YOOV Differentiation Nasdaq: ALBT 11 x AI - Powered, No - Code Platform – Accessible to all businesses; rapid deployment & shorter timelines. x Comprehensive AIaaS Ecosystem – Modules like Operations AI, People AI, Sales AI; integrates with credit & insurance. x Smart Solutions with Scalability – Au
Slide 12: YOOV Growth Strategy
YOOV Growth Strategy • Expanding Market Presence – AIaaS market forecasted CAGR of 36.8% (2025 – 2030); scaling offerings across finance, healthcare, retail, and manufacturing. • Global Expansion – Initial focus on Southeast Asia, followed by Australia, New Zealand, and Middle East to broaden geogra
Slide 13: Senior Management Team
Senior Management Team David Jin, M.D., Ph.D. CEO, President, Co - founder, BoD U.S. Licensed Physician; Former Medical Resident, Fellow and Faculty Member at Weill Cornell Medicine and New York - Presbyterian Hospital; Senior Clinician - Scientist at Ansary Stem Cell Institute; Former CMO of BioTim
Slide 14: Avalon Board of Directors
Avalon Board of Directors Nasdaq: ALBT 14 Steven Sanders, J.D. Director, Co - Chair of Compensation Committee Founder of Ortoli Rosenstadt Law Firm, NYC William Stilley Director, Chairman of Audit Committee CEO of Purnovate, an Adial company (NASDAQ: ADIL) Lourdes Felix Director, Chief Executive Off
Slide 15: Capitalization
Capitalization 3 . 8 M Common Shares Outstanding (As of August 13, 2025) Nasdaq: ALBT 15 $ 2 . 02 Stock Price 24 . 4 % Insider Ownership (As of April 24, 2025) 7 . 67 M Market Cap 1 1 1.Based on Nasdaq closing price on August 29 , 202 5
Slide 16: Contact
www.avalon - globocare.com Nasdaq: ALBT Contact: Avalon Executive Center 4400 Route 9 South, Suite 3100 Freehold, New Jersey 07728, USA Website: www.avalon - globocare.com IR Email: albt@crescendo - ir.com Thank You
Avalon GloboCare — Merger or Acquisition (September 2025) on 6ix